ClinicalTrials.gg
Active, not recruitingNCT07730762Updated Jul 28, 2026

A Study of Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) for Insomnia During Pregnancy

An interventional study of transcutaneous auricular vagus nerve stimulation and sham taVNS stimulation in Insomnia, sponsored by Xijing Hospital. Active, not recruiting at 1 site in China. Open to female participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-07-28.

Sponsored by Xijing Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 10 months after the study started (first participant enrolled Aug 2024, registered Jul 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 198 studies in Sleep Initiation and Maintenance Disorders with a site in China — 82 open to participants now, 88 under way, 2 of them phase 3. Sleep Initiation and Maintenance Disorders · China.

Planned enrollment
35th of 162
200 · median 88
Started
2024
with 44 others
No phase
123 of 198
56 open now
Primary completion
2026-11
later than 48 of 87 live
Registered
185th of 198
by date
Lead sponsor
7 of 198
Xijing Hospital

Among the 198 studies in Sleep Initiation and Maintenance Disorders with a site in China, this one is the 35th largest by planned enrollment of the 162 interventional ones that give a count, is one of 45 that started in 2024, is one of 123 with no phase, reaches primary completion later than 48 of the 87 other live ones, and was the 185th registered.

Sleep Initiation and Maintenance Disorders

2,738 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 735 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

82 of the 198 studies in Sleep Initiation and Maintenance Disorders with a site in China are open now. Recruiting first, the newest first:

77 more — sign in →

All 82 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 394 Sleep Initiation and Maintenance Disorders studies recruiting now, 156 (40%) set no upper age limit and 208 (53%) stop at 75 or younger; 61 take children under 18; 112 take healthy volunteers.

This study: 18 Years to 35 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies in Sleep Initiation and Maintenance Disorders with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn whether transcutaneous auricular vagus nerve stimulation (taVNS) can treat insomnia during pregnancy. It will also learn about the safety of taVNS for pregnant women and their fetuses. The main questions it aims to answer include:

Can taVNS improve sleep quality in patients with gestational insomnia, as measured primarily by the Insomnia Severity Index (ISI)? Compared with a 2-week delayed intervention, can starting taVNS intervention 2 weeks earlier lead to superior improvements in sleep and mood outcomes? Does taVNS have any adverse effects on maternal electrocardiogram, fetal ultrasound, or fetal heart rate? What medical problems (adverse events) do participants experience when receiving taVNS treatment? Researchers will compare active taVNS with sham stimulation (the device looks and operates the same but delivers no effective current), while also incorporating a delayed-intervention group (no intervention during the first 2 weeks) as a temporal control, to observe whether taVNS can treat gestational insomnia and whether earlier intervention offers additional advantages.

Participants will:

Receive active taVNS or sham stimulation according to their randomized group assignment during specified time periods, at a frequency of 2-3 times daily, 30 minutes per session, for 14 consecutive days (the early-intervention group begins immediately upon enrollment; the late-intervention group has a 2-week waiting period after enrollment before starting intervention; the early-intervention group undergoes crossover at Day 15).

Complete a 3-day pre-trial period after enrollment for device operation training and individualized stimulation intensity setting.

Attend hospital follow-up visits at baseline (Day 0), Day 15, and Day 30 to complete sleep assessments (ISI, AIS, PSQI, ESS) and mood assessments (HAMA, HAMD).

Undergo repeated maternal electrocardiogram, fetal ultrasound, and fetal heart rate monitoring before and after treatment to evaluate safety.

Maintain a daily treatment diary (recording usage time, frequency, and any adverse symptoms), with device-internal usage logs cross-checked against diaries to ensure adherence.

03

Conditions studied

  • Insomnia

Keywords

  • Pregnant participants
  • Insomnia
  • transcutaneous auricular vagus nerve stimulation
04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Females aged 18-35 years, gestational age 20-34 weeks. Stable physical condition confirmed by routine laboratory tests (complete blood count, liver function, renal function, thyroid-stimulating hormone), urine toxicology screening, and (ECG) at screening.

Fetal ultrasound and fetal heart rate monitoring performed and assessed by an obstetrician-gynecologist prior to enrollment.

Insomnia symptoms meeting all of the following criteria:

At least one of: (a) sleep onset latency > 30 minutes; (b) nocturnal awakenings ≥ 2 times/night; (c) total sleep time \< 6 hours; (d) accompanied by daytime dysfunction.

Symptoms occur despite adequate opportunity and appropriate circumstances for sleep.

At least one sleep-related daytime impairment: fatigue/malaise; impaired attention/memory; decreased academic/occupational/social functioning; mood disturbances/irritability; daytime sleepiness; reduced interest/energy; increased errors during work or driving; tension/headache/dizziness or other somatic symptoms related to sleep deficiency.

Symptoms persisted for ≥ 2 weeks. Confirmed eligible for enrollment by both an obstetrician and a neurologist. Willing and able to provide signed .

Exclusion criteria

Exclusion Criteria:

  • History of psychiatric disorders prior to pregnancy. History of psychoactive substance abuse. Prior exposure to taVNS (transcutaneous auricular vagus nerve stimulation) treatment.

Cardiac arrhythmia, particularly bradycardia. Currently receiving hypnotic medications or other insomnia treatments. Known fetal abnormalities (e.g., intrauterine growth restriction, congenital malformations, or cardiac rhythm abnormalities detected on fetal ultrasound).

History of adverse pregnancy outcomes or current pregnancy with known obstetric complications (e.g., gestational hypertension, gestational diabetes, or abnormal prenatal examination results).

Deemed unsuitable for enrollment following assessment by either the obstetrician or neurologist.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Early intervention group: active taVNS first, then sham stimulation (crossover at Day 15)

    Device: transcutaneous auricular vagus nerve stimulation

  • Experimental
    Early intervention group: sham stimulation first, then active taVNS (crossover at Day 15)

    Device: transcutaneous auricular vagus nerve stimulation

  • Experimental
    Late intervention group: 2-week waiting period first, followed by 2 weeks of active taVNS

    Device: transcutaneous auricular vagus nerve stimulation

  • Sham comparator
    Late intervention group: 2-week waiting period first, followed by 2 weeks of sham taVNS

    Device: sham taVNS stimulation

Interventions

  • Devicetranscutaneous auricular vagus nerve stimulation

    The taVNS parameters were set at a pulse width of 200 μs and a frequency of 30 Hz.

  • Devicesham taVNS stimulation

    The taVNS parameters were set at a pulse width of 200 μs and a frequency of 10 Hz.

06

What researchers measure

Primary outcomes

  1. Insomnia Severity Index (ISI)

    Time frame: Change from baseline in Insomnia Severity Index (ISI) at week 2 and week 4

  2. Epworth Sleepiness Scale (ESS)

    Time frame: Change from baseline in Epworth Sleepiness Scale (ESS)at week 2 and week 4.

  3. Pittsburgh Sleep Quality Index (PSQI)

    Time frame: Change from baseline in Pittsburgh Sleep Quality Index (PSQI) at week 2 and week 4.

Secondary outcomes

  1. Hamilton Anxiety Rating Scale (HAMA)

    Time frame: Change from baseline in Hamilton Anxiety Rating Scale (HAMA) at week 2 and week 4.

  2. Hamilton Depression Rating Scale (HAMD)

    Time frame: Change from baseline in Hamilton Depression Rating Scale (HAMD) at week 2 and week 4.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — all collected IPD

Supporting information: Study protocol, Statistical analysis plan

Time frame: starting 6 months after publication

Data sharing details ↗ · ngdc.cncb.ac.cn

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Nov 2026, 27 months after the start.

Of 1,219 non-industry interventional studies with no phase under Sleep Initiation and Maintenance Disorders, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 35. This study's planned 27 months is above that.

Counting every sponsor, half of 1,297 studies reached it within 15 months; a quarter within 6 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2026
First posted
Jul 28, 2026
StartActual
Aug 30, 2024
Primary completionEst.
Nov 30, 2026
CompletionEst.
Dec 31, 2026
Last update
Jul 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07730762
Lead sponsor
Xijing Hospital
Responsible party
Sponsor
First posted
Jul 28, 2026
Start date
Aug 30, 2024
Primary completion
Nov 30, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jul 28, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion